RELAY, Erlotinib Plus Ramucirumab in Untreated, EGFR-Mutated, Metastatic NSCLC: Outcomes by EGFR Exon 19 Deletion Variants

Nishino, KazumiKazumiNishinoJIN-YUAN SHIHNakagawa, KazuhikoKazuhikoNakagawaReck, MartinMartinReckGaron, Edward BEdward BGaronCarlsen, MichelleMichelleCarlsenMatsui, TomokoTomokoMatsuiVisseren-Grul, CarlaCarlaVisseren-GrulNadal, ErnestErnestNadal2024-02-232024-02-232024-0226663643https://scholars.lib.ntu.edu.tw/handle/123456789/639917EGFR gene mutations are drivers of NSCLC. The RELAY double-blind, placebo (PBO)-controlled phase 3 study revealed superior progression-free survival (PFS) for ramucirumab plus erlotinib (RAM + ERL) versus PBO (PBO + ERL) in patients with untreated advanced NSCLC and an EGFR-activating mutation. This exploratory analysis evaluated potential associations between EGFR exon 19 deletion (ex19del) variants and clinical outcomes.enCarcinoma; EGFR exon 19 deletion variant; Non–small cell lung; Ramucirumab; Targeted therapy; VEGFR inhibitionRELAY, Erlotinib Plus Ramucirumab in Untreated, EGFR-Mutated, Metastatic NSCLC: Outcomes by EGFR Exon 19 Deletion Variantsjournal article10.1016/j.jtocrr.2023.100624383048572-s2.0-85184759186https://api.elsevier.com/content/abstract/scopus_id/85184759186